CRAFA
PEPTIDE & COMPOUND ANALYSIS

Independent Peptide & Research-Compound Testing
14 Mill Lane, Cambridge, United Kingdom

CERTIFICATE OF ANALYSIS

Certificate of Analysis (COA)

No. CRF-2026-0142
Issued: 2026-09-03

PRODUCT IDENTIFICATION

PRODUCT Semaglutide	SKU / INTERNAL CODE CRF-2026-0142	PRESENTATION Lyophilised powder, 5 mg vial
BATCH NUMBER CRF-2026-0142	SAMPLE RECEIVED 2026-08-28	PRODUCTION DATE 2026-08-24
ANALYSIS DATE 2026-09-01	EXPIRY / RETEST DATE 2028-09-01	MOLECULAR FORMULA (REFERENCE) C187H291N45O59
MOLECULAR WEIGHT (G/MOL; REFERENCE) 4113.58	CAS (REFERENCE) 910463-68-2	

Research Use Only (RUO). Not for human or veterinary use, consumption, or clinical diagnosis.

ANALYTICAL METHOD — HPLC

INSTRUMENT Thermo Q-Exactive	COLUMN C4 2.1×100mm	COLUMN TEMPERATURE 60°C
MOBILE PHASE A 0.1% TFA H2O	MOBILE PHASE B 0.1% TFA ACN	FLOW RATE 0.3 mL/min
DETECTION WAVELENGTH 214 nm	INJECTION VOLUME 5 µL	SAMPLE CONCENTRATION 0.5 mg/mL
DILUENT —	RETENTION TIME (MAIN PEAK) 12.8 min	

Recorded methods: HPLC-UV (214 nm) · LC-MS/MS (Q-Exactive) · LAL

RESULTS

Test	Acceptance Criteria	Result	Verdict
HPLC Purity (% area)	≥98.0%	99.9%	PASS
Identity (LC-MS)	4114.6 ±2%	Obs: 4113.58 [M+H]+	PASS
Quantity found	95.0–105.0%	4.92 mg (98.4%)	PASS
Endotoxin	<1.0 EU/mg	<0.5 EU/mg	PASS
Heavy metals	<10 ppm	All <LOQ	PASS

Detected Impurities

No impurity data recorded.

FINAL BATCH RESULT

PASS — Conforms to specifications

No chromatogram data recorded.

Analyst notes: Compound conforms to all label claims. Minor d-amino impurity at 0.4% (within acceptable range).

crafa

CRAFA